kynostatin 272 has been researched along with didanosine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Chokekijchai, S; Mitsuya, H; Shirasaka, T; Weinstein, JN | 1 |
| Kavlick, MF; Kosalaraksa, P; Mitsuya, H; Yusa, K | 1 |
1 review(s) available for kynostatin 272 and didanosine
| Article | Year |
|---|---|
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
2 other study(ies) available for kynostatin 272 and didanosine
| Article | Year |
|---|---|
In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Interactions; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Structure; Oligopeptides; Phytohemagglutinins; Zidovudine | 1995 |
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Topics: Animals; Anti-HIV Agents; Cell Line, Transformed; COS Cells; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis; Oligopeptides; Polymerase Chain Reaction; Recombination, Genetic; Reverse Transcriptase Inhibitors; Transfection; Virus Replication; Zalcitabine; Zidovudine | 1997 |